Next in Pharma: The 2025 Outlook—The Future is Now

PwC's Next in Health

Tune in as PwC's Pharmaceutical & Life Sciences Advisory Leader, Greg Rotz reflects on key market dynamics and explores how pharma leaders can tackle challenges including the $400 billion patent cliff, increasing competition, drug pricing pressures, and transformative disruptions shaping the industry. Discussion highlights:

• Understanding the scale and implications of the upcoming patent cliff and economic pressures from regulatory changes like the Inflation Reduction Act
• Examining heightened competition across therapeutic areas and the rapid emergence of rival treatments affecting market economics
• Highlighting the necessity for bold strategic moves and critical capabilities, including AI innovation, portfolio optimization, strategic partnerships, and comprehensive risk management
• Addressing disruptive forces such as geopolitical uncertainty, tariff impacts, and the rise of global innovation influencing pharmaceutical markets
• Emphasizing the urgency for pharma leaders to embrace innovation and transformative strategies to improve healthcare affordability, accessibility, and quality

Speakers:

Greg Rotz, Pharmaceutical & Life Sciences Leader,PwC
Glenn Hunzinger, Health Industries Leader, PwC
Jenny Colapietro, Consulting Commercial Leader, PwC

Linked materials:

Next in pharma 2025: The future is now

Pharmaceutical and life sciences: US Deals 2025 outlook

President Donald J. Trump’s healthcare agenda

For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.